3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Breast Neoplasms
1
Interventions
Cisplatin
274
pembrolizumab
229
Radiotherapy
166
Cetuximab
163
Carboplatin
122
Docetaxel
109
Paclitaxel
94
Fluorouracil
94
Nivolumab
84
Radiotherapy, Intensity-Modulated
78
Magnetic Resonance Spectroscopy
39
durvalumab
35
Radiation
32
Surgical Procedures, Operative
31
Drug Therapy
30
Radiosurgery
25
Erlotinib Hydrochloride
25
Biopsy
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Platinum
22
Specimen Handling
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Capecitabine
19
tremelimumab
18
Ipilimumab
18
Gemcitabine
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Squamous Cell Carcinoma of Head and Neck
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts